The encoded BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity, which activates multiple downstream signaling pathways, resulting in uncontrolled cell proliferation, aberrant differentiation, and inhibition of apoptosis, thereby driving the development of chronic myeloid leukemia (CML). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.